stockportfolio.pro
Corcept Therapeutics Incorporated (CORT)
Healthcare · Biotechnology · NasdaqCM
Corcept Therapeutics Incorporated revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $81.32M | $159.20M | $251.25M | $306.49M | $353.87M | $365.98M | $401.86M | $482.38M | $675.04M | $761.41M |
| Gross profit | $79.26M | $155.65M | $246.03M | $300.98M | $348.29M | $360.70M | $396.47M | $475.89M | $664.16M | $748.43M |
| Net income | $8.14M | $129.12M | $75.41M | $94.18M | $106.01M | $112.51M | $101.29M | $105.50M | $139.73M | $98.17M |
| Net margin | 10.0% | 81.1% | 30.0% | 30.7% | 30.0% | 30.7% | 25.2% | 21.9% | 20.7% | 12.9% |
Source: Corcept Therapeutics Incorporated SEC filings (10-K). 26 years of history available in the interactive view.
What growth is priced into CORT stock?
At today's market cap of $8.36B, Corcept Therapeutics Incorporated is priced for free-cash-flow growth of about 22.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $141.78M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -1.2%/yr over the last five fiscal years and revenue 16.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 26 years of Corcept Therapeutics Incorporated financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CORT in your portfolio →
Corcept Therapeutics Incorporated financial history by metric
About Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.
Corcept Therapeutics Incorporated — frequently asked questions
What is Corcept Therapeutics Incorporated's revenue?
Corcept Therapeutics Incorporated (CORT) reported revenue of $761.41M for fiscal year 2025, up 12.8% from the prior year, according to its SEC filings.
Is Corcept Therapeutics Incorporated profitable?
Yes. CORT earned net income of $98.17M in fiscal 2025, a net margin of 12.9%.
What is CORT's P/E ratio?
Corcept Therapeutics Incorporated trades at a price-to-earnings ratio of about 222.6 based on the latest data in our nightly-refreshed cache.
How fast is Corcept Therapeutics Incorporated growing?
CORT's revenue grew at roughly 16.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Corcept Therapeutics Incorporated have?
As of fiscal year 2025, CORT carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Corcept Therapeutics Incorporated's gross margin?
CORT's gross margin was 98.3% in fiscal 2025 — gross profit of $748.43M on revenue of $761.41M.
What is Corcept Therapeutics Incorporated's market cap?
Corcept Therapeutics Incorporated (CORT) has a market capitalization of about $8.36B, based on the latest data in our nightly-refreshed cache.
When does Corcept Therapeutics Incorporated's fiscal year end?
CORT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into CORT stock?
At today's market cap of $8.36B, Corcept Therapeutics Incorporated is priced for free-cash-flow growth of about 22.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $141.78M from the FY ending 2025-12-31). For comparison, free cash flow actually grew -1.2%/yr over the last five fiscal years and revenue 16.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Corcept Therapeutics Incorporated's official SEC filings (10-K and 10-Q), covering 26 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.